🧬 Moderna’s Personalized Cancer Vaccine
In a Phase 3 trial, Moderna’s personalized mRNA vaccine intismeran, combined with Merck’s Keytruda, extended recurrence-free and distant metastasis-free survival in high-risk melanoma patients after surgery. Moderna shares surged.
The vaccine targets each tumor’s neoantigens. It is the first successful late-stage trial for an individualized mRNA cancer therapy.
✔️ @venture
🧬 Moderna’s Personalized Cancer Vaccine In a Phase 3 trial, Moderna’s personalized mRNA vaccine inti
Venture Capital
@ventureThe official channel of V3V Ventures. We share updates on our investments, portfolio companies, and fund activities. Buy Ads: @strategy (this is our only account).
2,289,290 subscribers
Open in Telegram